Low-Dose Colchicine Reduced Ischemic CV Event Risk Irrespective of Prior MI
The anti-inflammatory benefits of colchicine were consistently observed in this study, regardless of specific history and timing of prior ACS.
All articles by Endocrinology Advisor Contributing Writer
SHPT, Hyperphosphatemia Linked to CV Event Incidence in Chronic Kidney Disease
The primary objective of this study was to assess whether the potential independent effects of secondary hyperparathyroidism on the risk for CKD progression and cardiovascular event incidence in CKD patients act as effect modifiers.
ALI Risk High After Stent Graft Thrombosis Even With Low Amputation Risk
The researchers’ goal was to determine the clinical impact of stent graft thrombosis and its prognosis.
COVID-19 Increases Health Inequities in Patients With Hypertension
This report draws on the work of several sources, including a diverse group of experts at a recent conference that discussed health inequities magnified by the COVID-19 pandemic.
Microvascular Complications Linked to Reduced Global Longitudinal Strain in Diabetes
Albuminuria, retinopathy, and periphery neuropathy were all microvascular complications associated with reduced left ventricle systolic function.
Large Proportion of Hospitalized Patients May Have Undiagnosed Hypertension
A large retrospective observational study found large numbers of hospitalized patients with blood pressures exceeding thresholds for hypertension.
Statins Reduce MACE in Diabetes Without Obstructive CAD
The researchers studied the effect of aspirin and statin treatment on cardiovascular and bleeding incidence in patients with diabetes in the absence of obstructive CAD.
Finerenone Reduces New-Onset AF in Patients With CKD and T2D
Because finerenone inhibits cardiac remodeling in preclinical models, investigators sought to examine its effect on new-onset AFF by analyzing data from the FIDELIO-DKD phase 3 trial.
AHA/ASA 2021 Guidelines for Secondary Stroke Prevention
Here are highlights from the American Heart Association and American Stroke Association’s 2021 evidence-based guidelines for preventing another stroke after a first stroke or transient ischemic attack.
Suboptimal Use of SGLT2 Inhibitors in Individuals With Diabetes and Heart Failure
A team of investigators assessed the frequency with which patients with type 2 diabetes and heart failure were prescribed sodium-glucose co-transporter 2 inhibitors.
- Loading...
Loading...
Next post in AACE 2021
Loading... 
Loading...